- Home
- KUKE vs IBIO Comparison
KUKE vs IBIO Comparison
Compare KUKE & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- IBIO
- Stock Information
- Founded
- KUKE 2002
- IBIO 2008
- Country
- KUKE China
- IBIO United States
- Employees
- KUKE N/A
- IBIO N/A
- Industry
- KUKE Other Consumer Services
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- IBIO Health Care
- Exchange
- KUKE Nasdaq
- IBIO Nasdaq
- Market Cap
- KUKE 21.2M
- IBIO 24.3M
- IPO Year
- KUKE 2021
- IBIO N/A
- Fundamental
- Price
- KUKE $0.33
- IBIO $2.41
- Analyst Decision
- KUKE
- IBIO Strong Buy
- Analyst Count
- KUKE 0
- IBIO 3
- Target Price
- KUKE N/A
- IBIO $4.87
- AVG Volume (30 Days)
- KUKE 124.2K
- IBIO 98.8K
- Earning Date
- KUKE 12-31-2024
- IBIO 02-07-2025
- Dividend Yield
- KUKE N/A
- IBIO N/A
- EPS Growth
- KUKE N/A
- IBIO N/A
- EPS
- KUKE N/A
- IBIO N/A
- Revenue
- KUKE $14,784,158.00
- IBIO $175,000.00
- Revenue This Year
- KUKE N/A
- IBIO N/A
- Revenue Next Year
- KUKE N/A
- IBIO N/A
- P/E Ratio
- KUKE N/A
- IBIO N/A
- Revenue Growth
- KUKE 10.48
- IBIO 250.00
- 52 Week Low
- KUKE $0.23
- IBIO $1.02
- 52 Week High
- KUKE $4.07
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- KUKE 41.48
- IBIO 45.02
- Support Level
- KUKE $0.30
- IBIO $2.24
- Resistance Level
- KUKE $0.37
- IBIO $2.75
- Average True Range (ATR)
- KUKE 0.05
- IBIO 0.23
- MACD
- KUKE 0.01
- IBIO -0.03
- Stochastic Oscillator
- KUKE 33.96
- IBIO 23.29
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.